Pyxis Oncology reports Q3 net loss of $22 mln

Reuters

11/03

<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> reports Q3 net loss of $22 mln

Overview

Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year
Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025
Expected cash runway through data milestones into second half of 2026

Outlook

Pyxis Oncology expects preliminary data from MICVO studies in 4Q25
Company anticipates cash runway into second half of 2026
Pyxis Oncology to announce next steps in MICVO development with data update

Result Drivers

G&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees
TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.35
Q3 Net Income		-$22 mln
Q3 Basic EPS		-$0.35
Q3 Income from Operations		-$23.46 mln

Press Release: ID:nGNX6XTnxk

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580290360"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580290360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580290360?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580290360","market":"us","top_or_hot":-1,"title":"Pyxis Oncology reports Q3 net loss of $22 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> reports Q3 net loss of $22 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year</p></li><li><p>Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025</p></li><li><p>Expected cash runway through data milestones into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pyxis Oncology expects preliminary data from MICVO studies in 4Q25</p></li><li><p>Company anticipates cash runway into second half of 2026</p></li><li><p>Pyxis Oncology to announce next steps in MICVO development with data update</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>G&amp;A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees</p></li><li><p>TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$23.46 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6XTnxk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology reports Q3 net loss of $22 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology reports Q3 net loss of $22 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PYXS\">Pyxis Oncology</a> reports Q3 net loss of $22 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pyxis Oncology reports Q3 net loss of $22 mln, consistent with prior year</p></li><li><p>Company anticipates preliminary data from MICVO Phase 1 studies in Q4 2025</p></li><li><p>Expected cash runway through data milestones into second half of 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Pyxis Oncology expects preliminary data from MICVO studies in 4Q25</p></li><li><p>Company anticipates cash runway into second half of 2026</p></li><li><p>Pyxis Oncology to announce next steps in MICVO development with data update</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>G&amp;A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting fees</p></li><li><p>TRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodeling</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.35</p></td><td></td></tr><tr><td><p>Q3 Income from Operations</p></td><td></td><td><p>-$23.46 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6XTnxk</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL1N3WF0DM:1","article_id":"2580290360","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580290360","pubTimestamp":1762172153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pyxis Oncology reports Q3 net loss of $22 mlnOverviewPyxis Oncology reports Q3 net loss of $22 mln, consistent with prior yearCompany anticipates preliminary data from MICVO Phase 1 studies in Q4 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PYXS":"Pyxis Oncology, Inc."},"translate_title":"Pyxis Oncology报告第三季度净亏损2200万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":0.9},"content_text":"Pyxis Oncology reports Q3 net loss of $22 mlnOverviewPyxis Oncology reports Q3 net loss of $22 mln, consistent with prior yearCompany anticipates preliminary data from MICVO Phase 1 studies in Q4 2025Expected cash runway through data milestones into second half of 2026OutlookPyxis Oncology expects preliminary data from MICVO studies in 4Q25Company anticipates cash runway into second half of 2026Pyxis Oncology to announce next steps in MICVO development with data updateResult DriversG&A COSTS FALL - The decrease was primarily due to lower corporate insurance costs and a decrease in legal, professional and consulting feesTRANSLATIONAL INSIGHTS - New data presented at ESMO and AACR-NCI-EORTC highlight MICVO's mechanism of action and potential benefits in tumor microenvironment remodelingKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.35Q3 Net Income-$22 mlnQ3 Basic EPS-$0.35Q3 Income from Operations-$23.46 mlnPress Release: ID:nGNX6XTnxkFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}